Navigation Links
BIOSAFE Launching In a New Specially-Treated Facemask Effective Against H1N1 Influenza

PITTSBURGH, Oct. 13 /PRNewswire/ -- BIOSAFE, Inc., a company that manufactures and sells a novel antimicrobial polymer, has announced that they are launching in specific markets outside the United States through a unique facemask treated with BIOSAFE(®). Crosstex' new BIOSAFE-treated Ultra Sensitive facemasks begin to reduce microorganisms such as MRSA, VRE, and Staph immediately upon contact, and have further proven to be effective against Influenza A strains such as seasonal flu and the novel H1N1 virus.

Gary Steinberg, CEO of Crosstex, stated, "Facemasks serve as the first line of defense against airborne particles by trapping them in the filter media. However, live microorganisms can continue to live on the mask surface. Our new BIOSAFE treated Ultra Sensitive facemasks enhance the functionality of the mask by actually killing the harmful microorganisms, reducing the cross-contamination risk from touching the mask itself, and creating a safer environment upon disposal of the mask. The BIOSAFE treatment additive, as approved by the EPA, was compatible with our manufacturing process. We were attracted to the product since it chemically binds to the outer mask surface creating a long-lasting shield against microbial contamination and, because BIOSAFE mechanically kills cells, therefore will not cause development of more resistant 'superbugs'."

Max Fedor, President and CEO of BIOSAFE declared, "In the simplest terms, BIOSAFE's HM4100 is better, faster, and less costly as an antimicrobial additive. It provides protection for the life of the product and because of the way it works it does not promote adaptive organisms or 'superbugs'. Our product's safety is unparalleled and it has passed all required toxicity tests and received an EPA label. It has also passed USP / ISO biocompatibility tests that are normally required for medical device materials."

He continued, "The worldwide market for antimicrobials is $6 billion and some of the solutions historically deployed need to be upgraded to improved science such as BIOSAFE's. Our product is non-leaching, has no volatile organic compounds (VOCs), heavy metals, or polychlorinated phenols. We provide significant benefits in manufacturability thereby reducing hurdles to adoption, while lowering the ultimate costs in the process."

Cantel's President and CEO, Andrew Krakauer explained, "BIOSAFE is an important component of our strategic plans to expand our liquid chemical germicide business and invest more aggressively in research & development. Given the unique performance, manufacturability, and cost advantages of this additive, Cantel has embarked on a number of internal R&D initiatives to incorporate BIOSAFE into a variety of its other products." Mr. Krakauer continued, "We have invested significant dollars, resources, and time towards this goal and it has been a fantastic cross-divisional effort that demonstrates how we are gaining leverage from the expertise in our different companies."

Within the United States, the sale of facemasks treated with BIOSAFE antimicrobial for medical applications is subject to a 510(k) clearance by the U.S. Food and Drug Administration. At this time the Company is awaiting publication of the latest revision of the FDA Guidance Document pertaining to antimicrobial treatments of medical devices prior to the filing of its application. The Company is in the process of submitting an application with the U.S. Environmental Protection Agency covering the sale of treated masks in the United States for non-medical applications.

About BIOSAFE, Inc.

Pittsburgh-based BIOSAFE, Inc., has been funded by Pittsburgh Life Sciences Greenhouse, Innovation Works, and Bluetree Allied Angels, manufactures and sells an antimicrobial polymer, HM 4100. HM4100 is effective in defending against bacteria, fungi (mold and mildew), yeast, algae, and even certain viruses. BIOSAFE's patented technology is an excellent antimicrobial additive for treating plastics, textiles, metals, ceramics, and activated carbon, with superior performance and economic benefits. For further information, visit the BIOSAFE website at .

About Crosstex International

A division of Cantel Medical Corp., Crosstex manufactures a wide array of infection prevention and control products for the healthcare industry. Founded in 1953 and headquartered in Hauppauge, New York, Crosstex sells branded and private label products including face masks, which are 100% manufactured in its FDA-registered New York facility. Sold in more than 100 countries, Crosstex products include sterilization pouches and accessories, patient towels and bibs, eyewear, surface disinfectants and deodorizers, germicidal wipes, hand sanitizer, gloves, sponges, cotton products, needles and syringes, scalpels and blades, sharps containers, saliva ejectors and evacuator tips. For further information, visit the Crosstex website at

About Cantel Medical Corp.

Cantel Medical Corp. (NYSE: CMN) is a leading provider of infection prevention and control products in the healthcare market. Our products include specialized medical device reprocessing systems for renal dialysis and endoscopy, dialysate concentrates and other dialysis supplies, disposable infection prevention and control products primarily for the dental industry, water purification equipment, sterilants, disinfectants and cleaners, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens. For more information please visit

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.


Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Hampshire Rx Card Launching Statewide
2. Lilly Advances Second Alzheimers Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials
3. Cantel Medicals Crosstex Subsidiary Launches New Specially Treated Face Mask Effective Against H1N1 Influenza
4. Breast-Specific Gamma Imaging Proves Cost-Effective for Pre-Surgical Planning of Patients with Known Cancer Diagnosis
5. HIV Vaccine Study First to Show Some Effectiveness in Preventing HIV
6. Medications Effective in Reducing Risk of Breast Cancer But Increase Risk of Adverse Effects, New Report Says
7. Researchers Find High-Dose Therapy for Liver Disease Not Effective
8. Clinical Study Proves Pollogens TriPollar(TM) Radio Frequency Technology is Effective in the Treatment of Stretch Marks
9. New Research Shows Effectiveness of Stereotactic Body Radiotherapy for Spinal Tumors
10. National Cancer Institute Research Identifies Unique Mechanism of Brostallicins Anti-Tumor Effectiveness
11. Reliv Internationals GlucAffect(TM) Proven Effective in Clinical Study
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  The American Academy ... Gynecologists (ACOG), and the March of Dimes cheered ... Protecting Our Infants Act of 2015 (S.799), ... of newborns born exposed to drugs, such as ... bill,s introduction, all three organizations have worked together ...
(Date:11/25/2015)... Nov. 25, 2015 AAIPharma Services Corp./Cambridge ... of at least $15.8  Million to expand its ... NC . The expansion will provide additional ... the growing demands of the pharmaceutical and biotechnology ... expansion will provide up to 40,000 square feet ...
(Date:11/25/2015)... USA , Inc., a leader in ... accuracy of its blood glucose meter systems. Last week ... Cardiovascular Disease in Los Angeles , ... 01 meter and the Assure ® Prism multi-user ... measure glucose levels in blood is essential for people ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... , ... A team of Swiss doctors has released a report on mesothelioma ... posted the findings on the website. Click here to read the details now. ... patients who were treated with chemotherapy followed by EPP surgery. Among the 106 patients ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced ... offering customers 10% off of their purchase of lice treatment product. In addition, customers ... According to a company spokesperson. “Finding lice is a sure way to ruin the ...
(Date:11/27/2015)... ... ... No.1 Herpes-only dating community in the world, revealed that over 50% of its members are ... people under the age of 50 – or 67% of the population - are infected ... HSV-1 infection . , "The data shocks us highly!" said Michelle Li, Co-Founder of ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices ... show that delves into an array of issues that are presently affecting Americans. Dedicated ... open dialogue, this show is changing the subjects consumers focus on, one episode at ...
(Date:11/27/2015)... ... 2015 , ... CBD College is proud to announce that on ... accreditation to its Diagnostic Medical Sonography program. CBD College is honored to join this ... colleges and universities in the state of California make the cut. CBD College is ...
Breaking Medicine News(10 mins):